2026-2034年全球臨床腫瘤學次世代定序市場規模、佔有率、趨勢和成長分析報告

預計到 2034 年，臨床腫瘤學中次世代定序的市場規模將從 2025 年的 6 億美元成長到 22.9 億美元，2026 年至 2034 年的複合年成長率為 15.97%。

由於對精準癌症診斷的需求不斷成長，全球臨床腫瘤學領域次世代定序市場正經歷快速成長。次世代定序（NGS）技術能夠對腫瘤進行全面的基因組分析，從而支持標靶治療的發展。癌症發生率的上升以及人們對個人化治療方案認知的不斷提高，正在推動全球市場的擴張。

關鍵成長要素包括定序技術的進步和定序成本的降低。醫療機構擴大採用新一代定序（NGS）技術進行癌症早期檢測和病情進展監測。臨床研究的拓展和政府資助的增加進一步推動了市場成長。此外，製藥公司也正在利用基因組數據進行藥物研發和伴隨診斷。

展望未來，人工智慧驅動的生物資訊工具與液態生物檢體應用的融合有望推動市場發展。新興國家腫瘤醫療基礎設施的改善將創造新的成長機會。各公司正致力於提高檢測準確性並縮短處理時間。隨著精準腫瘤學逐漸成為標準治療方案，全球臨床腫瘤學次世代定序市場預計將持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球臨床腫瘤學次世代定序市場：依技術分類

• 市場分析、洞察與預測
• 全基因測序
• 全EXOME定序
• 標靶定序和定序

第5章：全球臨床腫瘤學次世代定序市場：依工作流程分類

• 市場分析、洞察與預測
• NGS定序預處理
• 次世代定序
• NGS數據分析

第6章：全球臨床腫瘤學次世代定序市場：按應用領域分類

• 市場分析、洞察與預測
• 篩檢（散發性癌症、遺傳性癌症）
• 伴隨診斷
• 其他診斷

第7章 全球臨床腫瘤學次世代定序市場：依最終用途分類

• 市場分析、洞察與預測
• 醫院
• 診所
• 研究所

第8章：全球臨床腫瘤學次世代定序市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Illumina Inc
  • Thermo Fisher Scientific
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies
  • Myriad Genetics
  • Beijing Genomics Institute（BGI）
  • PerkinElmer
  • Foundation Medicine
  • Pacific Biosciences（PacBio）
  • Oxford Nanopore Technologies Ltd
  • Paradigm Diagnostics
  • Caris Life Sciences
  • Partek Inc
  • Eurofins Scientific SE
  • Qiagen NV

The Clinical Oncology Next Generation Sequencing Market size is expected to reach USD 2.29 Billion in 2034 from USD 0.60 Billion (2025) growing at a CAGR of 15.97% during 2026-2034.

The Global Clinical Oncology Next Generation Sequencing Market is witnessing rapid growth due to increasing demand for precision cancer diagnostics. Next generation sequencing (NGS) enables comprehensive genomic profiling of tumors, supporting targeted therapy decisions. Rising cancer prevalence and growing awareness of personalized treatment approaches are driving market expansion worldwide.

Key growth drivers include advancements in sequencing technologies and decreasing sequencing costs. Healthcare providers are increasingly adopting NGS for early detection and monitoring of cancer progression. Expanding clinical research and supportive government funding are further strengthening market growth. Additionally, pharmaceutical companies are utilizing genomic data for drug development and companion diagnostics.

Looking ahead, the market is expected to benefit from integration of AI-driven bioinformatics tools and liquid biopsy applications. Emerging economies improving oncology care infrastructure will present new growth opportunities. Companies are focusing on enhancing accuracy and reducing turnaround times. As precision oncology becomes standard practice, the Global Clinical Oncology Next Generation Sequencing Market is poised for sustained growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing

By Workflow

• NGS Pre-Sequencing
• NGS Sequencing
• NGS Data Analysis

By Application

• Screening (Sporadic Cancer, Inherited Cancer)
• Companion Diagnostics
• Other Diagnostics

By End-use

• Hospitals
• Clinics
• Laboratories

COMPANIES PROFILED

• Illumina Inc, Thermo Fisher Scientific, F HoffmannLa Roche Ltd, Agilent Technologies, Myriad Genetics, Beijing Genomics Institute BGI, PerkinElmer, Foundation Medicine, Pacific Biosciences PacBio, Oxford Nanopore Technologies Ltd, Paradigm Diagnostics, Caris Life Sciences, Partek Inc, Eurofins Scientific SE, Qiagen NV
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. Whole Genome Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Whole Exome Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Targeted Sequencing & Resequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY WORKFLOW 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Workflow
• 5.2. NGS Pre-Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. NGS Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. NGS Data Analysis Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Screening (Sporadic Cancer, Inherited Cancer) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Companion Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Technology
  • 8.2.2 By Workflow
  • 8.2.3 By Application
  • 8.2.4 By End-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Technology
  • 8.3.2 By Workflow
  • 8.3.3 By Application
  • 8.3.4 By End-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Technology
  • 8.4.2 By Workflow
  • 8.4.3 By Application
  • 8.4.4 By End-use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Technology
  • 8.5.2 By Workflow
  • 8.5.3 By Application
  • 8.5.4 By End-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Technology
  • 8.6.2 By Workflow
  • 8.6.3 By Application
  • 8.6.4 By End-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Illumina Inc
  • 10.2.2 Thermo Fisher Scientific
  • 10.2.3 F. Hoffmann-La Roche Ltd
  • 10.2.4 Agilent Technologies
  • 10.2.5 Myriad Genetics
  • 10.2.6 Beijing Genomics Institute (BGI)
  • 10.2.7 PerkinElmer
  • 10.2.8 Foundation Medicine
  • 10.2.9 Pacific Biosciences (PacBio)
  • 10.2.10 Oxford Nanopore Technologies Ltd
  • 10.2.11 Paradigm Diagnostics
  • 10.2.12 Caris Life Sciences
  • 10.2.13 Partek Inc
  • 10.2.14 Eurofins Scientific S.E
  • 10.2.15 Qiagen N.V